Syros Pharmaceuticals Shares Plummet Premarket
Zacks.com on MSN22h
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary GoalShares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, ...
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial with ...
Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and ...
With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...
Renamed newcomer will be positioned between the Sonet and Seltos and go on-sale in early 2025 in India with South African market availability unknown at present.
Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The company’s shares closed yesterday at $2.73. Nadeau covers the ...
The upcoming Kia Syros will most likely be positioned between Sonet and Seltos, therefore, potentially creating a new segment ...
Kia Motors has officially announced its upcoming compact SUV, the Syros, anticipated to hit the global market in the coming weeks with a full launch likely early next year. This model, previously ...
Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback